Ventripoint
March 16, 2021
Ventripoint JV Begins Process to have Heart Analysis System Certified for use in COVID Patients in China
Toronto, Ontario – TheNewswire – March 16, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces that its partner, Yutian Medical Shanghai Inc. (“Yutian”), has reported Chinese guidelines for the diagnosis and treatment of COVID-19 patients now…...
March 9, 2021
Ventripoint Passes Regulatory Inspection of Manufacturing Facility and Audit of Quality Assurance System
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce the Company has completed another successful NRTL inspection of their manufacturing facility for the manufacture of the VMS+ 3.0....
March 3, 2021
Ventripoint Diagnostics Receives Additional Innovation Assistance Program Funding and Updates Warrant Exercises
Toronto, Ontario – TheNewswire – March 3 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces that it is receiving an additional temporary wage grant of up to $43,353 as part of the National Research Council of…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that its partner, Yutian Medical Shanghai Inc. (“Yutian”), has reported a successful engagement with key opinion leaders in the echocardiography sector in China. A training session in…...
February 23, 2021
Ventripoint Heart Analysis System to be used at the Stollery Children’s Hospital to Study Atrial Dysfunction in Children
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is announcing the commencement of a new clinical study to measure atrial volumes and ejection fractions in children with suspected valvular disease. The study is being conducted by cardiologists in the…...
February 16, 2021
Ventripoint Advances Sales, Marketing, and Distribution Partnership in the Largest Market in World for Heart Disease: China
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to provide a corporate update on sales and marketing activities in China by our joint-venture partner Yutian Medical Shanghai Inc. (“Yutian”)....
February 9, 2021
Ventripoint Diagnostics Upgrades Investor Relations Webpage
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has released the company’s new Investor Relations (IR) section on the company’s website....
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) announces it has entered into an investor relations agreement with MarketSmart Communications Inc. pursuant to which MarketSmart will provide investor relations (IR) services to Ventripoint. The IR agreement is for an…...
February 4, 2021
Ventripoint Announces Complete Conversion of Secured Convertible Debentures, Exercise of Warrants and Accelerated Expiry Date of Warrants
Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) announces that all secured convertible debentures of the Company have been converted to common shares. This is an aggregated principle amount of $2,781,000, which was…...
January 11, 2021
Ventripoint Expands to Address the Needs of Companion Animals
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) announces that it has entered into a Collaboration Agreement with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography…...